According to international guidelines and consensus, patients with ulcerative colitis should be diagnosed to exclude radiation enteritis, infectious enteritis, tumor related diseases, etc;
Patients assessed as moderate to severe ulcerative colitis based on the Mayo score;
During the follow-up period, no relevant treatments (drugs and surgery) were used that could affect the assessment of the efficacy of biologics
You may not be if
Patients with hemodynamic instability;
Patients with obvious liver and kidney function injury: bilirubin, aminotransferase (ALT, AST) exceeded the upper limit of normal by 2 times; eGFR\<60ml/min or dialysis patients;
Patients allergic to IFX or VDZ;
Patients whose primary disease was gastrointestinal malignancy;
Patients currently suffering from serious or uncontrolled underlying diseases of the blood, digestive tract, metabolism, endocrine, lung, heart, nervous system, mental system, etc.;
Female patients during pregnancy and breastfeeding (including patients with reproductive needs);
Patients with current infection with infectious diseases (hepatitis B, hepatitis C, syphilis, AIDS, tuberculosis, etc.);
Patients who cannot cooperate with regular follow-up and review of laboratory indicators;
Any other circumstances which, in the opinion of the investigator, would render the subject unfit for study inclusion.
Clareo Health | Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis
